Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) shares plunged on Wednesday as traders reassessed the stock after an extreme, volume-driven rally.
The decline appeared stock-specific, with the Healthcare sector and S&P 500 each down only 0.1%.
The selloff followed a 322.6% surge to $2.95 during Monday’s regular session. Shares were already down 19.3% to $2.30 in Wednesday’s premarket trading before losses deepened.
Company Finds No Undisclosed Catalyst
Zhengye said it is unaware of any material non-public information, undisclosed transaction, or corporate development that would explain the recent price and volume moves.
